Can-Fite BioPharma (CANF) Operating Expenses (2014 - 2023)
Can-Fite BioPharma's (CANF) quarterly Operating Expenses came in at -$2.0 million in Q4 2023, down 51.6% YoY from -$4.1 million in Q4 2022, and up 3.49% on a QoQ basis from -$2.1 million in Q3 2023.
Can-Fite BioPharma (CANF) Operating Expenses (2014 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 10 years of Operating Expenses data on file, last reported at -$2.0 million in Q4 2023.
- Quarterly Operating Expenses fell 51.6% year-over-year to -$2.0 million in Q4 2023, while the trailing twelve-month figure through Jun 2025 was -$2.0 million (up 67.01% YoY) and the FY2025 annual result came in at -$10.4 million, down 17.62% from the prior year.
- Operating Expenses rose to -$2.0 million in Q4 2023, from -$2.1 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $2.0 million in Q1 2019 to a low of -$7.3 million in Q2 2019.
- A 5-year average of -$3.0 million and a median of -$2.8 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2020 — Operating Expenses slumped 322.59% — and 2022, when it surged 69.0%.
- Tracing CANF's Operating Expenses over 5 years: stood at -$4.8 million in 2019, then climbed by 22.9% to -$3.7 million in 2020, then decreased by 14.29% to -$4.2 million in 2021, then surged by 69.0% to -$1.3 million in 2022, then slumped by 51.6% to -$2.0 million in 2023.
- The last three Operating Expenses figures came in at -$2.0 million (Q4 2023), -$2.1 million (Q3 2023), and -$2.0 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.99 Mn |
| Sep 30, 2023 | -2.06 Mn |
| Jun 30, 2023 | -1.98 Mn |
| Mar 31, 2023 | -2.91 Mn |
| Dec 31, 2022 | -1.31 Mn |
| Sep 30, 2022 | -2.78 Mn |
| Jun 30, 2022 | -2.27 Mn |
| Mar 31, 2022 | -2.58 Mn |
| Dec 31, 2021 | -4.23 Mn |
| Sep 30, 2021 | -3.76 Mn |
| Jun 30, 2021 | -3.38 Mn |
| Mar 31, 2021 | -2.32 Mn |
| Dec 31, 2020 | -3.70 Mn |
| Sep 30, 2020 | -2.69 Mn |
| Jun 30, 2020 | -4.04 Mn |
| Mar 31, 2020 | -4.47 Mn |
| Dec 31, 2019 | -4.80 Mn |
| Sep 30, 2019 | -3.94 Mn |
| Jun 30, 2019 | -7.30 Mn |
| Mar 31, 2019 | 2.01 Mn |